ALT

Altimmune, Inc. Common Stock

5.09

USD

ALT Earnings Reports

Positive Surprise Ratio

ALT beat 22 of 31 last estimates.

71%

Next Report

Date of Next Report

Feb 25, 2026

Estimate for Q4 25 (Revenue/ EPS)

$717.00

-$0.04

Implied change from Q3 25 (Revenue/ EPS)

-85.66%

-80.95%

Implied change from Q4 24 (Revenue/ EPS)

-85.66%

-87.88%

Altimmune, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, ALT reported earnings of -0.21 USD per share (EPS) for Q3 25, beating the estimate of -0.28 USD, resulting in a 26.13% surprise. Revenue reached 5.00 thousand, compared to an expected 1.26 thousand, with a 296.20% difference. The market reacted with a +5.07% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.04 USD, with revenue projected to reach 717 USD, implying an decrease of -80.95% EPS, and decrease of -85.66% in Revenue from the last quarter.

FAQ

What were Altimmune, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Altimmune, Inc. Common Stock reported EPS of -$0.21, beating estimates by 26.13%, and revenue of $5.00K, 296.2% above expectations.

How did the market react to Altimmune, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 5.07%, changed from $3.75 before the earnings release to $3.94 the day after.

When is Altimmune, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 25, 2026.

What are the forecasts for Altimmune, Inc. Common Stock's next earnings report?

Based on 9 analysts, Altimmune, Inc. Common Stock is expected to report EPS of -$0.04 and revenue of $717.00 for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.